

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Scanlan Jacqueline</u>	2. Date of Event Requiring Statement (Month/Day/Year) <u>07/27/2017</u>	3. Issuer Name and Ticker or Trading Symbol <u>HAEMONETICS CORP [HAE]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>SVP, Global Human Resources</u>	5. If Amendment, Date of Original Filed (Month/Day/Year)
(Last) (First) (Middle) <u>400 WOOD ROAD</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
(Street) <u>BRAINTREE MA 02184</u>			
(City) (State) (Zip)			

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>4,122⁽¹⁾</u>	<u>D</u>	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Non-qualified Stock Option (Right to Buy)</u>	<u>03/06/2018</u>	<u>03/06/2024</u>	<u>Common Stock</u>	<u>5,197⁽²⁾</u>	<u>38.43</u>	<u>D</u>	
<u>Non-qualified Stock Option (Right to Buy)</u>	<u>06/06/2018</u>	<u>06/06/2024</u>	<u>Common Stock</u>	<u>11,558⁽²⁾</u>	<u>41.64</u>	<u>D</u>	

Explanation of Responses:

- Consists of Restricted Stock Unit grants which vest 25% per year over 4 years following the grant date. Grants were made under the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan.
- Grant of right to buy shares of common stock which are exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.

/s/ Alexander P. Steffan,
attorney-in-fact for Ms.
Scanlan

08/07/2017

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.